Clinical and Molecular Data to Predict Flares in DMARD optimization in Rheumatoid Arthritis: A Randomised, Controlled, Open-label, Non-inferiority Trial

2025-10-01 rheumatology Title + abstract only

Show abstract

ObjectivesOptimization of biological DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA) may be feasible in those who have maintained remission for at least six months. However, this approach carries the risk of disease flare, underscoring the need for reliable predictors to guide clinical decisions. MethodsThe OPTIBIO trial (EudraCT 2012-004482-40) was a phase IV, randomized, open-label, non-inferiority study conducted in five hospitals in Spain. RA patients in sustained remission on s...